Home' Australian Pharmacist : Australian Pharmacist September 2015 Contents Australian Pharmacist September 2015 I © Pharmaceutical Society of Australia Ltd.
Continuing Professional DeveloPment
KNOWLEDGE iN PRACTiCE
The challenge of applying what
you learn to pharmacy practice!
Knowledge in practice is designed to
be difficult and aims to make you apply
information from articles in this month’s
Australian Pharmacist and other suggested
reading to the questions below, just as you
would for a client/patient. this section is not
meant to be easy. there are no simple clear-
cut answers to the questions. the standard
references listed below may be of use when
answering the questions.
1. sansom ln, ed. australian pharmaceutical
formulary and handbook, 23rd edn. Canberra:
pharmaceutical society of australia; 2015.
2. rossi s, ed. australian medicines handbook.
adelaide: australian medicines handbook; 2015.
3. nps medicinewise. at: www.nps.org.au
4. merck manual of diagnosis and therapy.at: www.
5. product information – available from various
sources, e.g. mims, app guide or online on
6. royal College of pathologists of australasia. rCpa
manual. at: www.rcpamanual.edu.au
7. therapeutic guidelines series. etg complete.
melbourne: therapeutic guidelines limited.
Knowledge in practice
TO ANSWER KNOWLEDGE iN
answers for Knowledge in practice can only be
submitted online through the psa members-only
area of the psa website at: www.psa.org.au
psa members will receive instant feedback on
the correct answers with an explanation of why
the answer is correct. if you do not have member
access details for the psa website, you can request
them via a link from the login page.
Question 1. Medication review
Mr Finch (86 years old, 58 kg) is
referred for a residential medication
management review (RMMR). He has a
medical history of:
• atrial fibrillation
• ischaemic heart disease (STeMI 2004)
• macular degeneration (legally blind)
• osteoarthritis (hips, knees, back).
His current medications are:
• dabigatran (Pradaxa) 110 mg twice
• metoprolol (Minax) 50 mg twice daily
• colecalciferol (Ostevit-D) 25 mcg in the
• ferrous fumarate (Ferro-Tab) 100 mg
• glyceryl trinitrate (Nitrolingual
Pumpspray) 400 mcg 1–2 sprays when
• lactulose (Actilax) 15 mL when
required (used on average once per
• esomeprazole (Nexium) 20 mg in the
• paracetamol 500 mg/codeine 30 mg
(Panadeine Forte) 2 tablets 6-hourly
• sertraline (Zoloft) 100 mg in the
• ramipril (Tritace) 5 mg in the morning
• rosuvastatin (Crestor) 20 mg at night.
He describes his health as ‘fair’,
and complains that he is frequently
constipated and consequently feels
bloated. He also states that he has
been hospitalised twice in the past
three months with rectal bleeding,
and required a blood transfusion after
the first admission to correct the blood
loss. Despite this he does not want to
cease anticoagulation as his wife was
severely disabled following a stroke
several years ago and he does not want
to have the same happen to him.
which one of the following recommendations regarding mr finch’s management is the
a) recommend changing dabigatran to warfarin.
b) esomeprazole should be increased to 40 mg.
c) Consider changing sertraline to mirtazapine.
d) mr finch should commence regular docusate and senna.
through successful completion of this activity, the
learner will demonstrate their ability to:
• use readily available information sources to
access and select relevant and up-to-date
clinical and practice-based information
• promote and contribute to the optimal use of
• address primary healthcare needs of patients.
Competency standards (2010) addressed: 4.2,
6.1, 7.1, 7.2 .
Accreditation number: Cap150909f
6 OCTOBeR, 7:30–9:00PM AeST
upcoming national webinars
15 september – drug use trends in australia
6 october – Cardiovascular update
3 november – infant nutrition
Links Archive Australian Pharmacist August 2015 Australian Pharmacist October 2015 Navigation Previous Page Next Page